Daniela Delbeau on Individuals' Reactions to Cancer Treatments
Daniela Delbeau, RN, clinical research nurse coordinator at the Perlmutter Cancer Center at NYU Langone Medical Center, discusses how individuals react differently to treatment.
Daniela Delbeau, RN, clinical research nurse coordinator at the Perlmutter Cancer Center at NYU Langone Medical Center, discusses how individuals react differently to treatment.
While a drug, such as immunotherapy agents, may be deemed “ideal” for a specific cohort of patients, that does not necessarily mean that it will work and be ideal for each patient in the group. There are multiple factors that determine effectiveness of the drug, and when patients are not aware of this, they can get disappointed or frustrated with the results of a particular treatment.
Knowing the proper way to deal with these patients is important for oncology nurses, who must be aware of other treatment options to offer the patient if one is not working.
Stopping ICIs at 1 or 2 Years May Not Compromise Survival in HNSCC
September 11th 2024This retrospective, population-based study shows strong efficacy across multiple patient subgroups and different lines of therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Key Advances in Cancer Survivorship Toxicity Management
July 15th 2022In this episode of The Vitals, Lidia Schapira, MD, FASCO, recounts highlights from the 2022 ASCO Symptoms and Survivorship track and underscores key takeaways for practitioners seeking to enhance the delivery of cancer survivorship care.
Enfortumab Vedotin Plus Pembrolizumab Improves Outcomes vs Chemo in Urothelial Cancer
April 20th 2024Patients with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin plus pembrolizumab experienced a reduction in the risk for disease progression or death vs chemotherapy.
